Oncodona

Oncodona
Benefits
Indications

What is the Oncodona Test?

It is the most advanced genetic test for early identification of predisposition to inherited cancer.

Oncodona uses Next Generation Sequencing (NGS) to analyze genetic information present in a panel of 21 genes, including BRCA1 and BRCA2 genes, in order to locate harmful mutations.

The presence of a change or mutation in one of these genes assumes that the female carrier has an increased risk of developing breast and ovarian tumours, or other related cancers.

What is the procedure?

Why use Oncodona test?

The performance of the test, if positive, can be used to adopt follow-up and personalized early detection measures of the patient and their relatives.
Carriers already diagnosed will be more likely to have another type of cancer.
A positive test result may also have important health implications for family members, and even future generations.

What genes are included in the Oncodona test?

In addition to the BRCA1 and BRCA2 genes, the Oncodona test analyzes 19 more genes associated with risk of breast and ovarian cancer, which makes it a more complete test:

Who should use Oncodona test?

Women diagnosed with breast cancer and BRCA1 and BRCA2 negative genetic test. In these typesof patients Oncodona can find a mutation in up to 4% of women.
Women with a family member diagnosed with breast and ovarian cancer.
Women of general population without known increased risk.

Test limitations

It is reported that, in a particular case, the Oncodona test may not identify a mutation in the genes studied, even though a mutation may actually exist in one of the genes.
It is also reported that the Oncodona test can identify changes for which there is currently no medical consensus as to whether such changes pose an increased risk of developing cancer.
The Oncodona test does not include all genes for which the medical literature indicates a possible association with breast and/or ovarian cancer.

Documentation

Specialists documents

Brochure

Download

Scientific evidence

Relevant related studies:

Malone et al. Cancer Res 2006;66(16):8297-8308

JAMA Oncol. 2015;1(7):943-951. doi:10.1001/jamaoncol. 2015.2690

Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003.

Igenomix e la fertilità

Igenomix è un laboratorio di analisi mediche specializzato nei servizi di genetica riproduttiva. Alla Igenomix lavoriamo affinché, nel mondo del futuro, l’infertilità non sia più un problema. Facciamo ricerca sulla riproduzione umana e sulla genetica riproduttiva in collaborazione con cliniche e medici specializzati di tutto il mondo, con l’obiettivo di cambiare la vita di quelle coppie che stanno cercando di concepire.

Scopri di più su Igenomix

Other services

CGT

Determina il rischio di avere un bambino affetto da una malattia genetica.

Maggiori informazioni

PGT-M

Prevenire la trasmissione di malattie monogeniche

Maggiori informazioni

PGT-A

Screening
genetico preimpianto

Maggiori informazioni

Igenomix secondo la stampa

IGENOMIX non è affiliata ad alcuna delle pubblicazioni o canali informativi elencati in precedenza. La copertura mediatica non costituisce opera di promozione di IGENOMIX o dei suoi prodotti.

Mutations in BRCA1 or BRCA2 genes are 20-fold higher in women with precocious breast cancer

Mutations in BRCA1 and BRCA2 account for ≈ 5% of breast cancers and 10-15% of ovarian cancers.

Oncodona test offers genetic counselling by experts

Oncodona analyzes a panel of 21 genes

What is the Oncodona Test?

What is the procedure?

Why use Oncodona test?

What genes are included in the Oncodona test?

Who should use Oncodona test?

Test limitations

Brochure

Relevant related studies:

Possiamo aiutarti?

Igenomix e la fertilità

Informazioni sulla genetica

NUOVI CORSI DISPONIBILI:

Non Invasive PGS, Maria Vera

CGT

PGT-M

PGT-A

Early risk detection of hereditary breast and ovarian cancer.

Mutations in BRCA1 or BRCA2 genes are 20-fold higher in women with precocious breast cancer

Mutations in BRCA1 and BRCA2 account for ≈ 5% of breast cancers and 10-15% of ovarian cancers.

Oncodona test offers genetic counselling by experts

Oncodona analyzes a panel of 21 genes

What is the Oncodona Test?

What is the procedure?

Why use Oncodona test?

What genes are included in the Oncodona test?

Who should use Oncodona test?

Test limitations

Brochure

Relevant related studies:

Possiamo aiutarti?

Igenomix e la fertilità

Informazioni sulla genetica

NUOVI CORSI DISPONIBILI:

Non Invasive PGS, Maria Vera

Other services

CGT

PGT-M

PGT-A

Igenomix secondo la stampa